HOME >> BIOLOGY >> NEWS
24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

Boston (Feb. 14, 2003) Preliminary 24-week data were presented today from the CONTEXT trial, an open-label, multi-center study evaluating the safety and efficacy of once-a-day (QD) or twice-a-day (BID) dosing of the investigational protease inhibitor (PI) GW433908 (908) boosted with ritonavir (908/r) compared to a third treatment arm with the PI lopinavir/ritonavir (LPV/r, Kaletra) BID in treatment-experienced patients with prior virologic failure. The medications in all three treatment arms were administered as part of combination therapy that included two reverse transcriptase inhibitors (RTIs). In this study, 908 was administered without food or fluid restrictions.

908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX).

The primary objective of CONTEXT is to assess antiretroviral response by measuring the time averaged change in viral load (vRNA) from baseline (AAUCMB) at 24 and 48 weeks. Similar efficacy responses were seen in both the 908/r regimens and the LPV/r regimen, meeting the primary endpoint of non-inferiority in this study at 24 weeks.

"In the preliminary analysis of 24-week data, the mean AAUCMB was comparable for all three treatment arms," said Edwin DeJesus, M.D., Infectious Disease Consultants, Altamonte Springs, Fla., lead investigator on the study.

"Although these results are from only 24 weeks of study, these Phase III data on the safety and efficacy of the investigational agent 908 as therapy for HIV in PI-experienced patients with prior virologic failure are encouraging," said Doug Manion, M.D., vice president of Clinical Development, GSK.

CONTEXT is the third of three pivotal trials to support regulatory submission of 908. The 24-week CONTEXT results add to the 48-week results of the NEAT trial, also presented today in Boston, and 48-week data from the SOLO trial, presented in November 2002 at the 6th
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
14-Feb-2003


Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, is ... fully 21 CFR Part 11-compliant email client designed to provide product vigilance departments ...
(Date:1/19/2017)... 2017 AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: ... aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... the listing of its common shares on the NASDAQ ... "AquaBounty,s listing on NASDAQ represents an important ... to the U.S. markets as we advance plans for ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of ... growth is accounted to two main factors. The first is the amazing customer ... vendors supplying FireflySci products all around the world. , 2016 was a tremendous sales ...
Breaking Biology Technology:
Cached News: